Rossari Biotech Limited, a speciality chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced Q4 FY21 revenues of Rs. 218.2 crore as against Rs. 159.5 crore, registering 36.8% growth. 

EBITDA for Q4 FY21 at Rs. 35.2 crore as against Rs. 24 crore, up by 46.7%, PAT stood at Rs. 22.2 crore as against Rs. 15.1 crore, higher by 47.1%, and EPS (Diluted) stood at Rs. 4.29 as against Rs. 3.06. 

FY21 revenues from operations stood at Rs. 709.3 crore as against Rs. 600.1 crore for FY20, higher by 18.2%. PAT stood at Rs. 80 crore as against Rs. 65.2 crore, higher by 22.7%. 

Commenting on the performance, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, Rossari Biotech Limited said, “Growth was primarily driven by a robust and continued uptick in sales in the HPPC segment led by higher offtake in hygiene products and anti-viral portfolio sales. In addition, normalization in demand and improved consumption across the TSC and AHN business lines assisted overall results." 

"In one of the key developments during the quarter, we have fully operationalized our state-of-the-art greenfield manufacturing facility at Dahej. We have seen a strong ramp-up in utilization levels from this facility in recent months, leading to healthy volumes particularly in the HPPC segment. Going forward, a strong upcoming pipeline of new product launches should enable us to sustainably ramp-up utilization levels at this unit over the next 3-4 years," commented Edward Menezes and Sunil Chari. 

Overall, we are confident that the stabilization of the demand environment and improved consumption will lead to stronger and sustainable growth in the quarters ahead added Edward Menezes and Sunil Chari.